Similarly, GH replacement whose SMD were significantly different from those in TP- or TPGH-treated TXOX rats (Table S6) were functionally linked to KEGG pathways associated to ribosome regulation, TCA cycle, oxidative phosphorylation, FoxO (e.g., Igf1, Tgfbr1, Homer3, Kras), FA degradation (e.g., Gcdh, Echs1, Ehhadh), glycolysis/gluconeogenesis, arginine biosynthesis (e.g. Sds, Mat1a, Pah, Otc, Cps1, Cth), and to diseases such as prostate cancer and NAFLD. Here, GH1 is linked to metabolic dysfunction-associated steatotic liver disease.